Evidence map›Paper›PMID 40660243›Full record

Observational studyBMC women's health2025

Correlations of phosphorylated Nrf2 with responses to neoadjuvant chemotherapy in patients with triple-negative breast cancer.

Jiaxuan Yu, Tianze Yao, Min Zhang, Bingxin Li, Jiping Xie, Yi Wan, Zhantian Zhang, Shiyu Yang, Yuchuan Ge, Guangze Sun and 1 more

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in BMC women's health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jiaxuan Yu *Health Management Center, Affiliated Zhongshan Hospital of Dalian University, Dalian, 116001, China.
Tianze Yao *Department of Clinical Medicine, Jinzhou Medical University, Jinzhou, 121001, China.
Min ZhangDepartment of Breast and Thyroid Surgery, Affiliated Zhongshan Hospital of Dalian University, 6 Jiefang Street, Dalian, 116001, China.
Bingxin LiDepartment of Breast and Thyroid Surgery, Affiliated Zhongshan Hospital of Dalian University, 6 Jiefang Street, Dalian, 116001, China.
Jiping XieDepartment of Breast and Thyroid Surgery, Affiliated Zhongshan Hospital of Dalian University, 6 Jiefang Street, Dalian, 116001, China.
Yi WanDepartment of Breast and Thyroid Surgery, Affiliated Zhongshan Hospital of Dalian University, 6 Jiefang Street, Dalian, 116001, China.
Zhantian ZhangDepartment of Breast and Thyroid Surgery, Affiliated Zhongshan Hospital of Dalian University, 6 Jiefang Street, Dalian, 116001, China.
Shiyu YangDepartment of Breast and Thyroid Surgery, Affiliated Zhongshan Hospital of Dalian University, 6 Jiefang Street, Dalian, 116001, China.
Yuchuan GeDepartment of Breast and Thyroid Surgery, Affiliated Zhongshan Hospital of Dalian University, 6 Jiefang Street, Dalian, 116001, China.
Guangze SunDepartment of Breast and Thyroid Surgery, Affiliated Zhongshan Hospital of Dalian University, 6 Jiefang Street, Dalian, 116001, China.
Yongqiang YaoDepartment of Breast and Thyroid Surgery, Affiliated Zhongshan Hospital of Dalian University, 6 Jiefang Street, Dalian, 116001, China. dlyyq0411@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNeoadjuvant chemotherapy is the recommended treatment for stage II and III triple-negative breast cancer (TNBC). We aimed to study the role of phosphorylated Nrf2 (pNrf2) in the responses to neoadjuvant chemotherapy in TNBC patients.

methodsA prospective observational cohort study was performed in stage II and III TNBC patients who were scheduled for neoadjuvant chemotherapy between January 2017 and December 2021. The pre-treatment characteristics, including age, menses, tumor size and stages, and lymph node metastasis, were collected. The pNrf2 expression was determined by immunohistochemistry examination of tumor specimens obtained by pre-treatment core-needle biopsy. Post-treatment responses were evaluated as the clinical outcomes (RECIST) and pathological outcomes (Miller-Payne grading). Patients were assigned into either the low or high Nrf2 expression group. Their clinical characteristics and treatment responses were compared. Multivariate logistic regression analysis was performed to study the association between pNrf2 and pathological outcomes.

resultsIn total, 59 patients were included, with a mean age of 52.5 years old. There were 29 patients in the low pNrf2 group and 30 in the high pNrf2 group, respectively. The pre-treatment characteristics were comparable between the two groups. Compared with the low pNrf2 expression group, the high pNrf2 expression group had poorer clinical and pathological responses (P = 0.010 and < 0.001, respectively). Multivariate logistic regression analysis showed that the pNrf2 expression was negatively associated with the pathological response to neoadjuvant chemotherapy (odds ratio 0.033, 95% confidence interval 0.006-0.187).

conclusionsIn patients with TNBC, the pre-treatment pNrf2 expression was negatively correlated with the response to neoadjuvant chemotherapy.

Indexed as

Neoadjuvant TherapyNF-E2-Related Factor 2Triple Negative Breast NeoplasmsAdultChemotherapy, AdjuvantFemaleHumansMiddle AgedPhosphorylationProspective StudiesTreatment OutcomeNFE2L2 protein, humanNF-E2-Related Factor 2Neoadjuvant chemotherapyNuclear factor-erythroid factor 2-related factor 2PhosphorylationTreatment responseTriple-negative breast cancer

Identifiers

PMID40660243
PMCPMC12257656

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.